USA flag logo/image

An Official Website of the United States Government

Orally administered anti-TNFalpha RNAi therapeutic for autoimmune disorders

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95796
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AI091045
Solicitation Year:
N/A
Solicitation Topic Code:
NIAID
Solicitation Number:
N/A
Small Business Information
RXI PHARMACEUTICALS CORPORATION
1500 West Park Drive Suite 210 Westborough, MA 01581-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Orally administered anti-TNFalpha RNAi therapeutic for autoimmune disorders
Agency: HHS
Contract: 1R43AI091045-01
Award Amount: $597,088.00
 

Abstract:

DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant therapeutic paradigm, the ability to apply this technology to human afflictions, in particular, diseases associated with chronic inflammation, has been impeded by the absence of efficient, non-toxic and tissue-specific delivery systems. We have recently shown that P1 , 3-D-Glucan particles can be efficiently employed to deliver siRNAs to macrophages via oral administration (Aouadi, Tesz et al. 2009). As low dose, oral administration of chemically synthesized oligonucleotides was previously thought to be impossible, thi s discovery is viewed as a significant scientific breakthrough. The objective of this proposal is to employ this technology to develop a Glucan particle formulated with TNFalpha targeting siRNAs and validate this platform's efficacy in accepted models of i nflammation. Completion of this project is expected to enable rapid progression into the preclinical /clinical development of an orally administered anti-inflammatory drug, for autoimmune diseases such as inflammatory bowel disease, rheumatoid arthritis an d psoriasis. PUBLIC HEALTH RELEVANCE: RNAi (RNA interference) has large potential for the treatment of human disease. Efficient delivery is a major road block for therapeutic development. We have recently shown that 1, 3-D-Glucan particles can be effic iently employed to deliver siRNAs to macrophages via oral administration (Aouadi, Tesz et al. 2009). Completion of this project is expected to enable rapid progression into the preclinical /clinical development of an orally administered anti-inflammatory d rug, first for autoimmune diseases such as inflammatory bowel disease, rheumatoid arthritis and psoriasis.

Principal Investigator:

Anastasia Khvorova
5087673861
AKHVOROVA@RXIPHARMA.COM

Business Contact:

Mitchell T. Woolf
admin@rxipharma.com
Small Business Information at Submission:

RXI PHARMACEUTICALS CORPORATION
RXI PHARMACEUTICALS CORPORATION 60 PRESCOTT ST WORCESTER, MA -

EIN/Tax ID: 120809951
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No